primary antibodies to cd45  (Miltenyi Biotec)

Journal: The Journal of Clinical Investigation

Article Title: Immunotherapy targeting drug-tolerant Mycobacterium tuberculosis persisters accelerates tuberculosis cure in preclinical models

doi: 10.1172/JCI196648

Figure Lengend Snippet: ( A and B ) Representative lung sections (whole slides, rich DC–T cell fields of view and DC–T cell spatial plots) from RHZE alone ( A ) versus IN Mip3a/relMtb plus RHZE after 12 weeks of treatment ( B ) stained with antibodies for DAPI + only (dark blue, cell nuclei, top) or CD45 + (white, hematopoietic cells, bottom), CD45 + CD3 + (red, T cells, bottom), and CD45 + CD3 - CD11c + F4/80 – (yellow, DCs, bottom). Light brown arrows in low-magnification images (scale bars: 1 mm) indicate the specific areas shown in the corresponding high-magnification images (scale bars: 50 μm). Magenta arrows indicate DC–T cell colocalization. ( C and D ) Quantification of total DCls per DAPI + cells (percentage) and colocalization of DCs and T cells defined as the number of DCs within 10 μm of T cells (RHZE alone [ n = 6] vs. IN Mip3a/relMtb plus RHZE [ n = 4]). Assessment was performed on sections encompassing the entire left lung. * P < 0.05, by Mann-Whitney U test.

Article Snippet: Anti-CD45 primary antibody (1:200 dilution; Cell Signaling Technology, catalog 702575S) was applied at 36°C for 40 minutes.

Techniques: Staining, MANN-WHITNEY

Journal: bioRxiv

Article Title: An oncogenotype-immunophenotype paradigm governing the myeloid landscape in genetically engineered mouse models of prostate cancer

doi: 10.1101/2025.10.21.683668

Figure Lengend Snippet: A distinct myeloid cell distribution across different genotypes of tumor models. (A)Illustration for mouse models used in the study. (B) Kaplan-Meier plot of the survival analysis of four representative tumor models. (C) FACS analyses showing dichotomous infiltration of Ly6G + F4/80 − cells(neutrophils) and Ly6G−F480+ cells (macrophages) in four representative tumor models. Plots are gated on CD45 + CD11b+ cells. The experiments were repeated at least five times with similar results. (D) FACS analyses and quantification showing TIN percentage in the tumor microenvironment of vehicle- and SX-682-treated tumor-bearing mice. Plots are gated on CD45 + cells. (E) The bar plot of PS tumor weights of vehicle- and SX-682-treated tumor-bearing mice. (F) FACS analyses and quantification showing the percentage of CD3 + CD8 + T cells in the tumor microenvironment of vehicle- and SX-682-treated tumor-bearing mice. Plots are gated on CD45 + cells. (G) FACS analyses of T cell CFSE assay, showing the T cell proliferation after coculturing with TINs purified from PP, PS, PPS tumors. (H) Illustration of the central question: how tumor-intrinsic factors shape NES and MES TMEs to influence tumor progression. Statistical significance: ns p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, Unpaired nonparametric Mann Whitney test.

Article Snippet: Primary antibodies include anti-Mouse-CD45-FITC (Cytek Biosciences, 35-0451-U100, San Diego, CA, USA), anti-Mouse-CD11b-APC (Cytek Biosciences, 20-0112-U100, San Diego, CA, USA), anti-Mouse-Ly6G-PE-Cyanine7 (Cytek Biosciences, 60-1276-U100, San Diego, CA, USA), anti-Mouse-F4/80-PE (Cytek Biosciences, 50-4801-U100, San Diego, CA, USA), anti-Mouse-CD3-APC-Cyanine7 (Cytek Biosciences, 25-0032-U100, San Diego, CA, USA), anti-Mouse-CD8-APC (Cytek Biosciences, 20-0081-U100, San Diego, CA, USA), anti-Mouse-CD4-PE (Cytek Biosciences, 50-0041-U100, San Diego, CA, USA).

Techniques: CFSE Assay, Purification, MANN-WHITNEY